Click here to get full coverage on Rolls-Royce Signs Agreement to sell ITP Aero - Bain Capital

Rolls-Royce Signs Agreement to sell ITP Aero  Bain Capital

Rolls-Royce Signs Agreement to sell ITP Aero - Bain Capital

Click here to get full coverage on Maternal ITP History Masks SLE Uncovered by Immune-Mediated Neonatal Thrombocytopenia - Hematology Advisor

Maternal ITP History Masks SLE Uncovered by Immune-Mediated Neonatal Thrombocytopenia  Hematology Advisor

Maternal ITP History Masks SLE Uncovered by Immune-Mediated Neonatal Thrombocytopenia - Hematology Advisor

Click here to get full coverage on Sanofi’s New Study on Rilzabrutinib: A Potential Breakthrough for ITP Treatment - TipRanks

Sanofi’s New Study on Rilzabrutinib: A Potential Breakthrough for ITP Treatment  TipRanks

Sanofi’s New Study on Rilzabrutinib: A Potential Breakthrough for ITP Treatment - TipRanks

Click here to get full coverage on Novartis' ianalumab notches another Phase III win, now in ITP - FirstWord Pharma

Novartis' ianalumab notches another Phase III win, now in ITP  FirstWord Pharma

Novartis' ianalumab notches another Phase III win, now in ITP - FirstWord Pharma

Click here to get full coverage on Novartis scores 3rd phase 3 win for ianalumab this week - Fierce Biotech

Novartis scores 3rd phase 3 win for ianalumab this week  Fierce Biotech

Novartis scores 3rd phase 3 win for ianalumab this week - Fierce Biotech

Click here to get full coverage on Another Day Another Win For Novartis’s Ianalumab – This Time In ITP - insights.citeline.com

Another Day Another Win For Novartis’s Ianalumab – This Time In ITP  insights.citeline.com

Another Day Another Win For Novartis’s Ianalumab – This Time In ITP - insights.citeline.com

Click here to get full coverage on What to Know About Immune Thrombocytopenia (ITP) and COVID-19 - Verywell Health

What to Know About Immune Thrombocytopenia (ITP) and COVID-19  Verywell Health

What to Know About Immune Thrombocytopenia (ITP) and COVID-19 - Verywell Health

Click here to get full coverage on The gut-immune axis in primary immune thrombocytopenia (ITP): a paradigm shifts in treatment approaches - Frontiers

The gut-immune axis in primary immune thrombocytopenia (ITP): a paradigm shifts in treatment approaches  Frontiers

The gut-immune axis in primary immune thrombocytopenia (ITP): a paradigm shifts in treatment approaches - Frontiers

Click here to get full coverage on Voices in ITP Care: The Power of Shared Decision-Making - Sanofi

Voices in ITP Care: The Power of Shared Decision-Making  Sanofi

Voices in ITP Care: The Power of Shared Decision-Making - Sanofi

Click here to get full coverage on Novartis ianalumab Phase III trial meets primary endpoint in ITP, demonstrating statistically significant improvement in time to treatment failure - WebWire

Novartis ianalumab Phase III trial meets primary endpoint in ITP, demonstrating statistically significant improvement in time to treatment failure  WebWire

Novartis ianalumab Phase III trial meets primary endpoint in ITP, demonstrating statistically significant improvement in time to treatment failure - WebWire

Click here to get full coverage on Ianalumab's Breakthrough in ITP and Sjögren's Disease: A Paradigm Shift in B-Cell Targeted Autoimmune Therapies - AInvest

Ianalumab's Breakthrough in ITP and Sjögren's Disease: A Paradigm Shift in B-Cell Targeted Autoimmune Therapies  AInvest

Ianalumab's Breakthrough in ITP and Sjögren's Disease: A Paradigm Shift in B-Cell Targeted Autoimmune Therapies - AInvest

Click here to get full coverage on Diet Changes for People With Immune Thrombocytopenia - Everyday Health

Diet Changes for People With Immune Thrombocytopenia  Everyday Health

Diet Changes for People With Immune Thrombocytopenia - Everyday Health

Click here to get full coverage on Novartis’ antibody clinches another Phase 3 win, this time in a rare blood disease - Endpoints News

Novartis’ antibody clinches another Phase 3 win, this time in a rare blood disease  Endpoints News

Novartis’ antibody clinches another Phase 3 win, this time in a rare blood disease - Endpoints News

Click here to get full coverage on News | RTX's Pratt & Whitney adds ITP Aero to GTF MRO Network - RTX

News | RTX's Pratt & Whitney adds ITP Aero to GTF MRO Network  RTX

News | RTX's Pratt & Whitney adds ITP Aero to GTF MRO Network - RTX

Click here to get full coverage on Avatrombopag Is Safe and Effective in Pediatric Patients With Immune Thrombocytopenia - Hematology Advisor

Avatrombopag Is Safe and Effective in Pediatric Patients With Immune Thrombocytopenia  Hematology Advisor

Avatrombopag Is Safe and Effective in Pediatric Patients With Immune Thrombocytopenia - Hematology Advisor

Click here to get full coverage on Higher Mortality Rates Observed in Minority Patients Hospitalized With ITP - Hematology Advisor

Higher Mortality Rates Observed in Minority Patients Hospitalized With ITP  Hematology Advisor

Higher Mortality Rates Observed in Minority Patients Hospitalized With ITP - Hematology Advisor

Click here to get full coverage on Durable Platelet Response Seen With Rilzabrutinib in Patients With Persistent/Chronic ITP - Hematology Advisor

Durable Platelet Response Seen With Rilzabrutinib in Patients With Persistent/Chronic ITP  Hematology Advisor

Durable Platelet Response Seen With Rilzabrutinib in Patients With Persistent/Chronic ITP - Hematology Advisor

Click here to get full coverage on Phase 3 Study Assesses Efgartigimod in Treating Chronic Primary ITP - Hematology Advisor

Phase 3 Study Assesses Efgartigimod in Treating Chronic Primary ITP  Hematology Advisor

Phase 3 Study Assesses Efgartigimod in Treating Chronic Primary ITP - Hematology Advisor

Click here to get full coverage on Ofatumumab May Be Effective for Concomitant MS and ITP: A Case Report - Hematology Advisor

Ofatumumab May Be Effective for Concomitant MS and ITP: A Case Report  Hematology Advisor

Ofatumumab May Be Effective for Concomitant MS and ITP: A Case Report - Hematology Advisor

Click here to get full coverage on Serum Complement Levels May Serve as a Disease Activity Biomarker in ITP - Hematology Advisor

Serum Complement Levels May Serve as a Disease Activity Biomarker in ITP  Hematology Advisor

Serum Complement Levels May Serve as a Disease Activity Biomarker in ITP - Hematology Advisor

Click here to get full coverage on Rilzabrutinib Shows Sustained Platelet Responses in ITP - Hematology Advisor

Rilzabrutinib Shows Sustained Platelet Responses in ITP  Hematology Advisor

Rilzabrutinib Shows Sustained Platelet Responses in ITP - Hematology Advisor

Click here to get full coverage on The ITP "Stupid" Hackathon In The News - NYU Tisch School of the Arts

The ITP "Stupid" Hackathon In The News  NYU Tisch School of the Arts

The ITP "Stupid" Hackathon In The News - NYU Tisch School of the Arts

Click here to get full coverage on Impact of platelet transfusion and bleeding risk stratification in patients with immune thrombocytopenia before procedures - Nature

Impact of platelet transfusion and bleeding risk stratification in patients with immune thrombocytopenia before procedures  Nature

Impact of platelet transfusion and bleeding risk stratification in patients with immune thrombocytopenia before procedures - Nature

Click here to get full coverage on Generic Eltrombopag Expands Access and Flexibility in ITP and Severe Aplastic Anemia - OncLive

Generic Eltrombopag Expands Access and Flexibility in ITP and Severe Aplastic Anemia  OncLive

Generic Eltrombopag Expands Access and Flexibility in ITP and Severe Aplastic Anemia - OncLive

Click here to get full coverage on ITP invests in R&D hub to advance scaffolding protection products - Scaffmag

ITP invests in R&D hub to advance scaffolding protection products  Scaffmag

ITP invests in R&D hub to advance scaffolding protection products - Scaffmag

Click here to get full coverage on EDPR Australia - EDP Global

EDPR Australia - EDP Global

Click here to get full coverage on Novartis scores phase III wins for two ianalumab indications - European Pharmaceutical Review

Novartis scores phase III wins for two ianalumab indications  European Pharmaceutical Review

Novartis scores phase III wins for two ianalumab indications - European Pharmaceutical Review

Click here to get full coverage on Christina Tang, ITP Alum & Resident, Announced among NYU Production Lab's Inaugural Artists in Residence Program - NYU Tisch School of the Arts

Christina Tang, ITP Alum & Resident, Announced among NYU Production Lab's Inaugural Artists in Residence Program  NYU Tisch School of the Arts

Christina Tang, ITP Alum & Resident, Announced among NYU Production Lab's Inaugural Artists in Residence Program - NYU Tisch School of the Arts

Click here to get full coverage on Ianalumab Meets Primary Endpoint in Phase 3 Trial for Primary Immune Thrombocytopenia - HCPLive

Ianalumab Meets Primary Endpoint in Phase 3 Trial for Primary Immune Thrombocytopenia  HCPLive

Ianalumab Meets Primary Endpoint in Phase 3 Trial for Primary Immune Thrombocytopenia - HCPLive

Click here to get full coverage on Sharon De La Cruz, ITP faculty and alum, featured speaker at Serious Play Conference 2025 - NYU Tisch School of the Arts

Sharon De La Cruz, ITP faculty and alum, featured speaker at Serious Play Conference 2025  NYU Tisch School of the Arts

Sharon De La Cruz, ITP faculty and alum, featured speaker at Serious Play Conference 2025 - NYU Tisch School of the Arts

Click here to get full coverage on Abstract 392: Recurrent ischemic strokes in a patient with ITP, case report and literature review - American Heart Association Journals

Abstract 392: Recurrent ischemic strokes in a patient with ITP, case report and literature review  American Heart Association Journals

Abstract 392: Recurrent ischemic strokes in a patient with ITP, case report and literature review - American Heart Association Journals

Click here to get full coverage on Two phase III wins for Novartis in autoimmune diseases - BioWorld MedTech

Two phase III wins for Novartis in autoimmune diseases  BioWorld MedTech

Two phase III wins for Novartis in autoimmune diseases - BioWorld MedTech

Click here to get full coverage on Managing Bleeding Risk in Patients with ITP - AJMC

Managing Bleeding Risk in Patients with ITP  AJMC

Managing Bleeding Risk in Patients with ITP - AJMC

Click here to get full coverage on The 7 Major Immune Thrombocytopenia (ITP) Markets are Expected to Exhibit a CAGR Of 3.82% During 2025-2035, impelled by Advancements in Early Detection and Diagnostic Technologies - BioSpace

The 7 Major Immune Thrombocytopenia (ITP) Markets are Expected to Exhibit a CAGR Of 3.82% During 2025-2035, impelled by Advancements in Early Detection and Diagnostic Technologies  BioSpace

The 7 Major Immune Thrombocytopenia (ITP) Markets are Expected to Exhibit a CAGR Of 3.82% During 2025-2035, impelled by Advancements in Early Detection and Diagnostic Technologies - BioSpace

Click here to get full coverage on Volume Six of the Dumbo Projection Project Features ITP Student Cohort - NYU Tisch School of the Arts

Volume Six of the Dumbo Projection Project Features ITP Student Cohort  NYU Tisch School of the Arts

Volume Six of the Dumbo Projection Project Features ITP Student Cohort - NYU Tisch School of the Arts

Click here to get full coverage on TTP vs. ITP: Comparisons and more - Medical News Today

TTP vs. ITP: Comparisons and more  Medical News Today

TTP vs. ITP: Comparisons and more - Medical News Today

Click here to get full coverage on Announcing ITP Camp 2025! - NYU Tisch School of the Arts

Announcing ITP Camp 2025!  NYU Tisch School of the Arts

Announcing ITP Camp 2025! - NYU Tisch School of the Arts

Click here to get full coverage on Eltrombopag, Diacerein Combination Therapy Leads to Better Outcomes in ITP Compared With Eltrombopag Monotherapy - Hematology Advisor

Eltrombopag, Diacerein Combination Therapy Leads to Better Outcomes in ITP Compared With Eltrombopag Monotherapy  Hematology Advisor

Eltrombopag, Diacerein Combination Therapy Leads to Better Outcomes in ITP Compared With Eltrombopag Monotherapy - Hematology Advisor

Click here to get full coverage on Sanofi's Rilzabrutinib: A Catalyst for Rare Disease Innovation and Shareholder Value - AInvest

Sanofi's Rilzabrutinib: A Catalyst for Rare Disease Innovation and Shareholder Value  AInvest

Sanofi's Rilzabrutinib: A Catalyst for Rare Disease Innovation and Shareholder Value - AInvest

Click here to get full coverage on ITP Celebrates 100 Years of Red Burns - NYU Tisch School of the Arts

ITP Celebrates 100 Years of Red Burns  NYU Tisch School of the Arts

ITP Celebrates 100 Years of Red Burns - NYU Tisch School of the Arts

Click here to get full coverage on Sahal and Lita, ITP Student and Alumna, Win Rhizome Grant - NYU Tisch School of the Arts

Sahal and Lita, ITP Student and Alumna, Win Rhizome Grant  NYU Tisch School of the Arts

Sahal and Lita, ITP Student and Alumna, Win Rhizome Grant - NYU Tisch School of the Arts

Click here to get full coverage on GE Aerospace Grants ITP Aero License for CT7-2F1 Engine MRO, Expanding TrueChoice™ Network for Bell 525 Operators - GE Aerospace

GE Aerospace Grants ITP Aero License for CT7-2F1 Engine MRO, Expanding TrueChoice™ Network for Bell 525 Operators  GE Aerospace

GE Aerospace Grants ITP Aero License for CT7-2F1 Engine MRO, Expanding TrueChoice™ Network for Bell 525 Operators - GE Aerospace

Click here to get full coverage on How to Manage the Biggest Mental Health Impacts of Living With ITP - Everyday Health

How to Manage the Biggest Mental Health Impacts of Living With ITP  Everyday Health

How to Manage the Biggest Mental Health Impacts of Living With ITP - Everyday Health

Click here to get full coverage on Living with Idiopathic Thrombocytopenic Purpura (ITP) - News-Medical

Living with Idiopathic Thrombocytopenic Purpura (ITP)  News-Medical

Living with Idiopathic Thrombocytopenic Purpura (ITP) - News-Medical

Click here to get full coverage on Dapsone ‘Should Be Considered’ as Pediatric ITP Treatment, Research Shows - Docwire News

Dapsone ‘Should Be Considered’ as Pediatric ITP Treatment, Research Shows  Docwire News

Dapsone ‘Should Be Considered’ as Pediatric ITP Treatment, Research Shows - Docwire News

Click here to get full coverage on ITP/IMA Spring Show 2022! - NYU Tisch School of the Arts

ITP/IMA Spring Show 2022!  NYU Tisch School of the Arts

ITP/IMA Spring Show 2022! - NYU Tisch School of the Arts

Click here to get full coverage on Sarah Rothberg, ITP Faculty and Alumna, to showcase in an upcoming exhibit at Bitforms Gallery - NYU Tisch School of the Arts

Sarah Rothberg, ITP Faculty and Alumna, to showcase in an upcoming exhibit at Bitforms Gallery  NYU Tisch School of the Arts

Sarah Rothberg, ITP Faculty and Alumna, to showcase in an upcoming exhibit at Bitforms Gallery - NYU Tisch School of the Arts

Click here to get full coverage on ITP - NYU

ITP - NYU

Click here to get full coverage on Novartis' Ianalumab Meets Primary Endpoint in ITP Trial - MarketScreener

Novartis' Ianalumab Meets Primary Endpoint in ITP Trial  MarketScreener

Novartis' Ianalumab Meets Primary Endpoint in ITP Trial - MarketScreener

Click here to get full coverage on Upfront Therapy for ITP in Kids: New Drug a Game Changer? - Medscape

Upfront Therapy for ITP in Kids: New Drug a Game Changer?  Medscape

Upfront Therapy for ITP in Kids: New Drug a Game Changer? - Medscape

Click here to get full coverage on Novartis says Ianalumab Phase III trial meets primary endpoint in ITP - MarketScreener

Novartis says Ianalumab Phase III trial meets primary endpoint in ITP  MarketScreener

Novartis says Ianalumab Phase III trial meets primary endpoint in ITP - MarketScreener

Click here to get full coverage on Novartis shares edge higher after ianalumab hits key goals in Phase 3 trial - MSN

Novartis shares edge higher after ianalumab hits key goals in Phase 3 trial  MSN

Novartis shares edge higher after ianalumab hits key goals in Phase 3 trial - MSN

Click here to get full coverage on Melika Panbehchi and Ender Minyard, ITP Students, selected as 2025 HEAR US grantees - NYU Tisch School of the Arts

Melika Panbehchi and Ender Minyard, ITP Students, selected as 2025 HEAR US grantees  NYU Tisch School of the Arts

Melika Panbehchi and Ender Minyard, ITP Students, selected as 2025 HEAR US grantees - NYU Tisch School of the Arts

Click here to get full coverage on The CRISPR-associated adenosine deaminase Cad1 converts ATP to ITP to provide antiviral immunity - ScienceDirect.com

The CRISPR-associated adenosine deaminase Cad1 converts ATP to ITP to provide antiviral immunity  ScienceDirect.com

The CRISPR-associated adenosine deaminase Cad1 converts ATP to ITP to provide antiviral immunity - ScienceDirect.com

Click here to get full coverage on Novartis' Ianalumab and the Shifting Landscape of B-Cell Targeted Autoimmune Therapies - AInvest

Novartis' Ianalumab and the Shifting Landscape of B-Cell Targeted Autoimmune Therapies  AInvest

Novartis' Ianalumab and the Shifting Landscape of B-Cell Targeted Autoimmune Therapies - AInvest

Click here to get full coverage on ITP Alumni & Adjunct Faculty Featured in Exhibitions for Upstate Art Weekend - NYU Tisch School of the Arts

ITP Alumni & Adjunct Faculty Featured in Exhibitions for Upstate Art Weekend  NYU Tisch School of the Arts

ITP Alumni & Adjunct Faculty Featured in Exhibitions for Upstate Art Weekend - NYU Tisch School of the Arts

Click here to get full coverage on Mile Marker 2023, Issue 1: Cal-ITP - California Department of Transportation | Caltrans (.gov)

Mile Marker 2023, Issue 1: Cal-ITP  California Department of Transportation | Caltrans (.gov)

Mile Marker 2023, Issue 1: Cal-ITP - California Department of Transportation | Caltrans (.gov)

Click here to get full coverage on Amelia Winger-Bearskin, ITP Alum, Featured in NEW INC's DEMO Festival - NYU Tisch School of the Arts

Amelia Winger-Bearskin, ITP Alum, Featured in NEW INC's DEMO Festival  NYU Tisch School of the Arts

Amelia Winger-Bearskin, ITP Alum, Featured in NEW INC's DEMO Festival - NYU Tisch School of the Arts

Click here to get full coverage on Novartis ianalumab Phase III trial meets primary endpoint in ITP, demonstrating statistically significant improvement in time to treatment failure - MarketScreener

Novartis ianalumab Phase III trial meets primary endpoint in ITP, demonstrating statistically significant improvement in time to treatment failure  MarketScreener

Novartis ianalumab Phase III trial meets primary endpoint in ITP, demonstrating statistically significant improvement in time to treatment failure - MarketScreener

Click here to get full coverage on ITP Camp 2021 - NYU Tisch School of the Arts

ITP Camp 2021  NYU Tisch School of the Arts

ITP Camp 2021 - NYU Tisch School of the Arts

Click here to get full coverage on Adiponectin Assists Thrombopoietic Agents in ITP Treatment by Enhancing Myosin-9/Rab6A-Mediated Trafficking of c-Mpl in MKs - Wiley

Adiponectin Assists Thrombopoietic Agents in ITP Treatment by Enhancing Myosin-9/Rab6A-Mediated Trafficking of c-Mpl in MKs  Wiley

Adiponectin Assists Thrombopoietic Agents in ITP Treatment by Enhancing Myosin-9/Rab6A-Mediated Trafficking of c-Mpl in MKs - Wiley

Click here to get full coverage on Wyna Liu, ITP Alumna and Connections editor, interviewed by NYU Tisch - NYU Tisch School of the Arts

Wyna Liu, ITP Alumna and Connections editor, interviewed by NYU Tisch  NYU Tisch School of the Arts

Wyna Liu, ITP Alumna and Connections editor, interviewed by NYU Tisch - NYU Tisch School of the Arts

Click here to get full coverage on Idiopathic Thrombocytopenic Purpura Therapeutics Market, 2034 - Global Market Insights

Idiopathic Thrombocytopenic Purpura Therapeutics Market, 2034  Global Market Insights

Idiopathic Thrombocytopenic Purpura Therapeutics Market, 2034 - Global Market Insights

Click here to get full coverage on ITP Alums Priyanka Makin ('24) and Zoe Cohen ('23) to present work at CURRENTS Art & Technology Festival - NYU Tisch School of the Arts

ITP Alums Priyanka Makin ('24) and Zoe Cohen ('23) to present work at CURRENTS Art & Technology Festival  NYU Tisch School of the Arts

ITP Alums Priyanka Makin ('24) and Zoe Cohen ('23) to present work at CURRENTS Art & Technology Festival - NYU Tisch School of the Arts

Click here to get full coverage on Kate Hartman, ITP Alumna, has released the second edition of "Make: Wearable Electronics" - NYU Tisch School of the Arts

Kate Hartman, ITP Alumna, has released the second edition of "Make: Wearable Electronics"  NYU Tisch School of the Arts

Kate Hartman, ITP Alumna, has released the second edition of "Make: Wearable Electronics" - NYU Tisch School of the Arts

Click here to get full coverage on Case Report: A case of pediatric persistent refractory ITP responsive to avatrombopag - Frontiers

Case Report: A case of pediatric persistent refractory ITP responsive to avatrombopag  Frontiers

Case Report: A case of pediatric persistent refractory ITP responsive to avatrombopag - Frontiers

Click here to get full coverage on Case Report: Ofatumumab treatment for concomitant multiple sclerosis and idiopathic thrombocytopenic purpura - Frontiers

Case Report: Ofatumumab treatment for concomitant multiple sclerosis and idiopathic thrombocytopenic purpura  Frontiers

Case Report: Ofatumumab treatment for concomitant multiple sclerosis and idiopathic thrombocytopenic purpura - Frontiers

Click here to get full coverage on Novartis Reports Phase III Trials Success for Ianalumab in Sjögren’s Disease and Immune Thrombocytopenia - geneonline.com

Novartis Reports Phase III Trials Success for Ianalumab in Sjögren’s Disease and Immune Thrombocytopenia  geneonline.com

IT Tech Packaging Inc (ITP)

Price Chart

Key Statistics

Technicals

About ITP

Latest News

Rolls-Royce Signs Agreement to sell ITP Aero - Bain Capital

Maternal ITP History Masks SLE Uncovered by Immune-Mediated Neonatal Thrombocytopenia - Hematology Advisor

Sanofi’s New Study on Rilzabrutinib: A Potential Breakthrough for ITP Treatment - TipRanks

Advanced Charts

Top Gainers

Top Losers